Amgen is developing a biosimilar of the drug, ABP 959, and during last week’s 24th Congress of the European Hematology Association, held from June 13-16 in Amsterdam, the Netherlands, researchers reported on findings from a phase 1 trial of the proposed product.
Eculizumab (Alexion’s Soliris) is used to treat generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome, all rare and ultra-rare diseases. While effective in treating these diseases, the complement inhibitor is among the highest-cost biologics on the market, carrying a list price of approximately $500,000 per patient per year.
Amgen is developing a biosimilar of the drug, ABP 959, and during last week’s 24th Congress of the European Hematology Association, held June 13-16 in Amsterdam, the Netherlands, researchers reported on findings from a phase 1 trial of the proposed product.
The randomized, double-blind, single-dose, 3-arm, parallel-group study was conducted in 219 healthy volunteers. The volunteers were randomized to receive a 300-mg intravenous infusion of either the proposed biosimilar (n = 71), the EU reference (n = 74), or the US reference (n = 74). Serum samples were collected over 56 days.
The primary objectives were to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of the proposed biosimilar versus the EU and US references, assessed by area under the total serum concentration—time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and area between the effect curve (ABEC) of 50% total hemolytic complement activity (CH50).
Secondary PK endpoints included AUC from time 0 to the time of the last observed quantifiable concentration (AUClast) and maximum observed concentration (Cmax)
The geometric mean ratios of the PK and PD parameters after a single infusion were similar among all 3 groups; the 90% confidence intervals of the geometric mean ratios were fully contained within the prespecified bioequivalence margin of 0.80 to 1.25 for all PK (AUCinf, Cmax, AUClast) and PD (ABEC of CH50) evaluations.
There were no treatment-emergent adverse events (AEs) that led to discontinuation, nor were there any deaths. Five volunteers experienced a total of 8 serious AEs. In total, 8.8% of volunteers had binding antidrug antibodies during the study, and no neutralizing antibodies were detected.
According to the authors, these data show the PK and PD equivalence of the proposed biosimilar to eculizumab, and demonstrated similar safety and immunogenicity profiles.
Reference
Chow V, Pan J, Chien D, Mytych D, Hanes V. Pharmacokinetic and pharmacodynamic similarity of ABP 959 with eculizumab: results from a randomized, double-blind, single-dose, parallel-group study in healthy subjects. Presented at: the 24th European Hematology Association Congress; June 13-16, 2019; Amsterdam, the Netherlands. Abstract PF347.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.